TACROLIMUS
Drug
Sandoz Inc.
Total Payments
$2.1M
Transactions
119
Doctors
27
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $111,002 | 11 | 0 |
| 2020 | $326,076 | 41 | 2 |
| 2019 | $525,182 | 62 | 25 |
| 2018 | $376,620 | 2 | 0 |
| 2017 | $786,000 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.0M | 62 | 96.2% |
| Travel and Lodging | $60,981 | 12 | 2.9% |
| Consulting Fee | $19,078 | 4 | 0.9% |
| Food and Beverage | $395.82 | 4 | 0.0% |
| Education | $353.72 | 37 | 0.0% |
Payments by Type
Research
$2.0M
62 transactions
General
$80,808
57 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PROSPECTIVE STUDY COMPARING BRAND AND GENERIC IMMUNOSUPPRESSION ON TRANSPLANT OUTCOMES, ADHERENCE, AND IMMUNE RESPONSE | Sandoz Inc. | $786,000 | 0 |
| PROSPECTIVE STUDY COMPARING BRAND AND GENERIC IMMUNOSUPPRESSION ON TRANSPLANT OUTCOMES, ADHERENCE, & IMMUNE RESPONSE | Sandoz Inc. | $376,620 | 0 |
| A STAGED STUDY INCORPORATING A PHASE 1B, MULTICENTER, UNMASKED, DOSE ESCALATION EVALUATION OF SAFETY AND TOLERABILITY AND A PHASE 2, MULTICENTER, UNMASKED, RANDOMIZED, PARALLEL-GROUP, CONTROLLED, PROOF OF CONCEPT INVESTIGATION OF EFFICACY AND SAFETY OF ASP7317 FOR ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION | Astellas Pharma Global Development | $293,624 | 0 |
| A Staged Study Incorporating a Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability and a Phase 2, Multicenter, Unmasked, Randomized, Parallel-group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to Age-related Macular Degeneration | Astellas Pharma Global Development | $136,675 | 0 |
| Molecular markers to differentiate calcineurin inhibitor toxicity from immunological mechanisms associated with progression to kidney dysfunction in kidney transplant recipients | Astellas Pharma Global Development | $91,978 | 0 |
| A Phase 2a, Randomized, Open-label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients | Astellas Pharma Global Development | $91,750 | 0 |
| Tacrolimus Pregnancy RegistryNational Transplantation Pregnancy Registry NTPR | Astellas Pharma Global Development | $74,800 | 0 |
| A Staged Study Incorporating a Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability and a Phase 2, Multicenter, Unmasked, Randomized, Parallel Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to Age-related Macular Degeneration | Astellas Pharma Global Development | $61,063 | 0 |
| Once-a-day Tacrolimus Conversion Study The OneTAC Trial | Astellas Pharma Global Development | $58,000 | 0 |
| A Prospective, Pilot Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release Astagraf XL in HLA Sensitized Kidney Transplant Recipients | Astellas Pharma Global Development | $37,325 | 0 |
| A non-interventional post-authorization safety study (NI-PASS) of outcomes associated with the use of tacrolimus around conception, or during pregnancy or lactation using data from Transplant Pregnancy Registry International (TPRI) | Astellas Pharma Europe BV | $32,532 | 0 |
| A Prospective, Pilot Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in HLA Sensitized Kidney Transplant Recipients | Astellas Pharma Global Development | $3,250 | 0 |
| A Prospective, Pilot Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release Astagraf XL in HLA Sensitized Kidney Transplant Recipients | Astellas Pharma Global Development | $455.00 | 0 |
Top Doctors Receiving Payments for TACROLIMUS
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $2.0M | 62 |
| , MD | Internal Medicine | Los Angeles, CA | $36,903 | 10 |
| , MD | Transplant Surgery | San Francisco, CA | $24,166 | 4 |
| , MD | Transplant Surgery | Boston, MA | $16,906 | 5 |
| Amer Zeidan | Hematology & Oncology | New Haven, CT | $2,480 | 1 |
| , M.D | Hematology & Oncology | Chula Vista, CA | $19.06 | 2 |
| , MD | Urology | La Mesa, CA | $19.06 | 2 |
| , MD | Urology | Honolulu, HI | $19.06 | 2 |
| , MD | Specialist | Carolina, PR | $19.06 | 2 |
| , M.D | Internal Medicine | San Diego, CA | $19.06 | 2 |
| , MD | Urology | Pittsburgh, PA | $19.06 | 2 |
| , MD | Urology | Poway, CA | $19.06 | 2 |
| , MD | Urology | Fort Smith, AR | $19.06 | 2 |
| , M.D | Urology | La Mesa, CA | $19.06 | 2 |
| , MD | Urology | Knoxville, TN | $19.06 | 2 |
| , M.D | Urology | Paoli, PA | $19.06 | 2 |
| , M.D | Urology | Battle Creek, MI | $19.06 | 2 |
| , M.D | Medical Oncology | Brawley, CA | $19.06 | 2 |
| , MD | Urology | Royal Oak, MI | $19.06 | 2 |
| , M.D | Urology | Newport News, VA | $10.64 | 1 |
| , MD | Urology | Newport News, VA | $10.64 | 1 |
| , M.D | Urology | Wichita Falls, TX | $10.64 | 1 |
| , MD | Urology | Decatur, GA | $10.64 | 1 |
| , MD | Urology | Mattoon, IL | $10.64 | 1 |
| , MD | Urology | Lexington, KY | $8.42 | 1 |
Ad
Manufacturing Companies
- Sandoz Inc. $1.2M
- Astellas Pharma Global Development $851,400
- Astellas Pharma Inc $77,975
- Astellas Pharma Europe BV $32,532
- Astellas Pharma US Inc $353.72
Product Information
- Type Drug
- Total Payments $2.1M
- Total Doctors 27
- Transactions 119
About TACROLIMUS
TACROLIMUS is a drug associated with $2.1M in payments to 27 healthcare providers, recorded across 119 transactions in the CMS Open Payments database. The primary manufacturer is Sandoz Inc..
Payment data is available from 2017 to 2021. In 2021, $111,002 was paid across 11 transactions to 0 doctors.
The most common payment nature for TACROLIMUS is "Unspecified" ($2.0M, 96.2% of total).
TACROLIMUS is associated with 13 research studies, including "PROSPECTIVE STUDY COMPARING BRAND AND GENERIC IMMUNOSUPPRESSION ON TRANSPLANT OUTCOMES, ADHERENCE, AND IMMUNE RESPONSE" ($786,000).